Stanford prohibits direct commercial CME sponsorship

Share this article:

Stanford University School of Medicine has announced it will prohibit “new commercial funding for specific CME courses or programs” as of September 1, 2008.

After September 1, industry funds for CME must go through Stanford's Office of Continuing Medical Education, and cannot be designated for a particular course or program, according to a Stanford newsletter. Companies may only designate funding for general categories, such as medical, pediatric and surgical specialties, diagnostic and imaging technologies and disciplines, and heath policy and disease prevention, said the newsletter.

Stanford's decision comes at the behest of the Association of American Medical Colleges (AAMC), who urged all medical schools and teaching hospitals to prohibit direct CME sponsorship last June. The AAMC recommended that schools and hospitals establish a central CME office for the coordination of industry funds, and also outlined new strictures on gifts for physicians, and detailing practices.

The New York Times reported on August 26 that Stanford would become the sixth major medical school to adopt this CME funding policy, joining the University of Massachusetts Medical School, the University of Pittsburgh School of Medicine, the University of Colorado, the University of Kansas Medical Center and the University of California Davis School of Medicine.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.